Constantine joins Boston Pharmaceuticals from Sanofi, where he was Vice President and Chief Licensing Officer, responsible for the global business development function since 2014. In addition, the North American and European regional Business Development teams reported to him. Some of the notable transactions he was directly responsible for included Sanofi's $2.5 billion Immuno-Oncology pact with Regeneron, acquisition of the Rx to OTC rights for Cialis from Eli Lilly, and the purchase of Priority Review Vouchers from Biomarin and Retrophin.
Constantine brings extensive experience in Business Development with nearly 20 years of working in external innovation-focused roles in the biotech and pharma industries. He joined Sanofi following its acquisition of Genzyme in 2011, and assumed the role of regional head of Business Development for Sanofi's North American Pharmaceutical division. Prior to this position, he was a Vice President in Genzyme's Corporate Development group, which he joined in 2001.
Before Genzyme, Constantine served in various capacities at Eli Lilly and Company over a twelve-year period, including roles in Corporate Finance & Investment Banking as well as the Office of Alliance Management.
Constantine received an undergraduate degree in History as well as an MBA from Cornell University.